Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huosu Nourishing Stomach Oral Liquid is a Traditional Chinese Medicine (TCM) formulation being investigated as an adjuvant therapy for advanced gastric cancer and gastroesophageal junction adenocarcinoma. Developed by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with the Shanghai University of Traditional Chinese Medicine, it is typically administered in combination with standard chemotherapy regimens such as XELOX (capecitabine and oxaliplatin). The formulation is intended to support gastric function and potentially enhance the therapeutic efficacy of chemotherapy. Clinical research associated with this product includes the assessment of AKR1C1 (Aldo-keto reductase family 1 member C1) expression in gastric tissues, suggesting a potential role in modulating metabolic pathways or the tumor microenvironment relevant to cancer progression and chemoresistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huosu Nourishing Stomach Oral Liquid.